Company intelligence / Profile preview

ImmVira

Shenzhen, Guangdong, Chinaimmviragroup.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ImmVira has demonstrated promising efficacy, durability, and safety results from several phase I/II trials of its lead oncolytic virus product MVR-T3011 in both the United States and China. The product has received FDA Fast Track designation for recurrent/metastatic HNSCC. Recent clinical data were presented at ESMO2024 showing activity in high-risk BCG-failure NMIBC patients via intravesical administration.[1][4]

Therapeutic areas: Oncology
Modalities: Oncolytic viruses (replicating and non-replicating herpes simplex virus vectors)Drug delivery exosomes[1][5]
Industry: Biotech

Drug pipeline

10 assets

MVR-T3011

9 more assets in the full pipeline.

Partnerships

Shanghai Pharma – exclusive license agreement for commercialization of MVR-T3011 intratumoral program in China; strategic investment from Shanghai Healthcare Capital ("SHC"), managed by SIIC Capital.[3]

Beyond the preview

Go deeper on ImmVira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmVira.